A study, published in the Journal of Clinical Oncology, examined how nonsteroidal anti-inflammatory drugs affected all-cause mortality in colorectal cancer patients.
Polly Newcomb, MD, an epidemiologist at Seattle-based Fred Hutchinson Cancer Research Center, and colleagues conducted an observational study of 2,419 newly diagnosed patients in the Colon Cancer Family Registry.
Researchers divided the patients into groups: patients who took NSAIDs before the diagnosis, patients who took the drugs post-diagnosis, patients who quit using the drugs post-diagnosis and those who did not use the drugs.
Researchers followed up with the patients at a median 10.8 years after diagnosis.
Here's what you should know:
1. Approximately 42 percent regularly took NSAIDs in both aspirin and nonaspirin forms.
2. Approximately 381 patients died, 100 because of their CRC.
3. Postdiagnostic aspirin-only users have favorable survival and CRC-specific survival scores over nonusers. Patients who initiated aspirin use after diagnosis also had favorable scores.
4. Overall survival rate for patients who used NSAIDs after diagnosis differed through KRAS-mutation status. KRAS-mutations are common in colon cancers.
Patients who used NSAIDs after diagnosis had improved survival rates if they had KRAS wild-type tumors. NSAID use among those with KRAS-mutant tumors showed no improvement.
Researchers concluded, "Among long-term CRC survivors, regular use of NSAIDs after CRC diagnosis was significantly associated with improved survival in individuals with KRAS wild-type tumors."
More articles on gastroenterology:
Screening colonoscopy complication rates low, study says — 3 notes
Physicians Endoscopy purchases stake in Great South Bay Endoscopy & more: 5 GI practices in the news
GI leader to know: Dr. Ronald Feldman